Advertisement
Advertisement
U.S. markets open in 7 hours 25 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Cardiol Therapeutics Inc. (CRDL.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
2.6900+0.1600 (+6.32%)
At close: 04:00PM EST
Advertisement

Cardiol Therapeutics Inc.

2265 Upper Middle Road East
Suite 602
Oakville, ON L6H 0G5
Canada
289 910 0850
https://www.cardiolrx.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. David G. Elsley M.B.A., MBAPres, CEO & Director517.43kN/AN/A
Mr. Christopher J. Waddick C.A., CPA, M.B.A., MBA, CMACFO & Corp. Sec.204.38kN/AN/A
Mr. Bernard Lim B.Sc.Chief Operating Officer234.25kN/AN/A
Trevor BurnsInvestor RelationsN/AN/AN/A
Dr. Andrew Warwick HamerChief Medical OfficerN/AN/A1962
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Cardiol Therapeutics Inc., a clinical-stage biotechnology company, focuses on the research and development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, an ultra-pure and high concentration cannabidiol oral formulation for the treatment of in hospitalized COVID-19 patients with a prior history of risk factors for CVD; and has completed phase I clinical trials for the treatment of acute myocarditis and other inflammatory heart disease. The company is also developing a proprietary subcutaneous formulation of cannabidiol to achieve higher bioavailability for the treatment chronic heart failure. In addition, it develops proprietary nanotechnology to enable the distribution of water insoluble drugs within the blood circulation, enhance pharmacokinetics, and facilitate drug accumulation in the failing heart. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.

Corporate Governance

Cardiol Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement